424 related articles for article (PubMed ID: 32663537)
21. Long-Term Biochemical Control of a Prospective Cohort of Prostate Cancer Patients Treated With Interstitial Brachytherapy Versus Radical Prostatectomy.
Sanmamed N; Locke G; Crook J; Liu A; Raman S; Glicksman R; Chung P; Berlin A; Fleshner N; Helou J
Clin Oncol (R Coll Radiol); 2023 Apr; 35(4):262-268. PubMed ID: 36737311
[TBL] [Abstract][Full Text] [Related]
22. Patient-reported Quality of Life After SBRT, LDR, and HDR Brachytherapy for Prostate Cancer: A Comparison of Outcomes.
Paly JJ; Egleston BL; Wong JK; Burbure N; Sobczak ML; Hayes SB; Chen DYT; Horwitz EM; Hallman MA
Am J Clin Oncol; 2021 Apr; 44(4):131-136. PubMed ID: 33577175
[TBL] [Abstract][Full Text] [Related]
23. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.
Kollmeier MA; McBride S; Taggar A; Anderson E; Lin M; Pei X; Weiji S; Voros L; Cohen G; Yamada Y; Zelefsky MJ
Brachytherapy; 2017; 16(6):1091-1098. PubMed ID: 28838648
[TBL] [Abstract][Full Text] [Related]
24. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
Ko EC; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
[TBL] [Abstract][Full Text] [Related]
25. Prostate-specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low-dose-rate brachytherapy or external beam radiotherapy for localized prostate cancer.
Nishimura S; Ohashi T; Momma T; Sakayori M; Eriguchi T; Tanaka T; Yamashita S; Kosaka T; Oya M; Shigematsu N
Cancer Med; 2018 May; 7(5):1794-1801. PubMed ID: 29577651
[TBL] [Abstract][Full Text] [Related]
26. Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer.
Tanaka N; Asakawa I; Nakai Y; Miyake M; Anai S; Fujii T; Hasegawa M; Konishi N; Fujimoto K
BMC Cancer; 2017 Aug; 17(1):573. PubMed ID: 28841855
[TBL] [Abstract][Full Text] [Related]
27. A Pooled Analysis of Biochemical Failure in Intermediate-risk Prostate Cancer Following Definitive Stereotactic Body Radiotherapy (SBRT) or High-Dose-Rate Brachytherapy (HDR-B) Monotherapy.
Hegde JV; Collins SP; Fuller DB; King CR; Demanes DJ; Wang PC; Kupelian PA; Steinberg ML; Kamrava M
Am J Clin Oncol; 2018 May; 41(5):502-507. PubMed ID: 27322703
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer.
Tsumura H; Satoh T; Ishiyama H; Tabata K; Komori S; Sekiguchi A; Ikeda M; Kurosaka S; Fujita T; Kitano M; Hayakawa K; Iwamura M
J Contemp Brachytherapy; 2016 Apr; 8(2):95-103. PubMed ID: 27257412
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific antigen kinetics and metastasis-free survival in patients treated with external beam radiotherapy combined with high-dose-rate brachytherapy boost and androgen deprivation therapy for localized prostate cancer.
Miszczyk M; Magrowski Ł; Masri O; Jabłon'ska I; Nowicka Z; Krzysztofiak T; Wojcieszek P; Lipka-Rajwa A; Ciepał J; Depowska G; Chimiak K; Bylica G; Płoszka K; Łaszczych M; Majewski W
J Contemp Brachytherapy; 2022 Feb; 14(1):15-22. PubMed ID: 35233230
[TBL] [Abstract][Full Text] [Related]
30. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy versus conventionally fractionated external beam radiotherapy for low- and intermediate-risk prostate cancer.
Lee SH; Kim HJ; Kim WC
Asia Pac J Clin Oncol; 2016 Dec; 12(4):388-395. PubMed ID: 27461444
[TBL] [Abstract][Full Text] [Related]
31. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244
[TBL] [Abstract][Full Text] [Related]
33. Early Safety and Efficacy Profile of Homogeneously Dosed Salvage Stereotactic Body Radiotherapy (SBRT) for Intraprostatic Recurrences After Low Dose Rate (LDR) Brachytherapy.
Nikitas J; Cao M; Nickols NG; Valle L; Steinberg ML; Kishan AU
Clin Genitourin Cancer; 2023 Apr; 21(2):208-212. PubMed ID: 36739178
[TBL] [Abstract][Full Text] [Related]
34. Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.
Fukuda S; Seo Y; Shiomi H; Yamada Y; Ogata T; Morimoto M; Konishi K; Yoshioka Y; Ogawa K
J Radiat Res; 2014 Nov; 55(6):1114-21. PubMed ID: 24957754
[TBL] [Abstract][Full Text] [Related]
35. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer.
Kim HJ; Phak JH; Kim WC
Asia Pac J Clin Oncol; 2017 Feb; 13(1):21-27. PubMed ID: 26969216
[TBL] [Abstract][Full Text] [Related]
36. Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter?
Correa RJM; Morton G; Chung HT; Tseng CL; Cheung P; Chu W; Liu SK; McGuffin M; Shahid A; Davidson M; Ravi A; Helou J; Alayed Y; Zhang L; Mamedov A; Loblaw A
Radiother Oncol; 2022 Apr; 169():51-56. PubMed ID: 35151715
[TBL] [Abstract][Full Text] [Related]
37. Salvage Reirradiation Options for Locally Recurrent Prostate Cancer: A Systematic Review.
Zhong J; Slevin F; Scarsbrook AF; Serra M; Choudhury A; Hoskin PJ; Brown S; Henry AM
Front Oncol; 2021; 11():681448. PubMed ID: 34568012
[TBL] [Abstract][Full Text] [Related]
38. High dose-rate brachytherapy boost for intermediate risk prostate cancer: Long-term outcomes of two different treatment schedules and early biochemical predictors of success.
Helou J; D'Alimonte L; Loblaw A; Chung H; Cheung P; Szumacher E; Danjoux C; Ravi A; Deabreu A; Zhang L; Morton G
Radiother Oncol; 2015 Apr; 115(1):84-9. PubMed ID: 25770875
[TBL] [Abstract][Full Text] [Related]
39. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
[TBL] [Abstract][Full Text] [Related]
40. Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer.
Agarwal M; Chhabra AM; Amin N; Braccioforte MH; Molitoris JK; Moran BJ
Brachytherapy; 2018; 17(6):882-887. PubMed ID: 30143400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
